Saturday, October 24, 2026
RSS

Inside BCI

Brain-Computer Interface Industry News
Industry News Research Policy Opinion Market Moves
About Directory Glossary
Policy & Regulation

US Treasury proposes barring new US private investment in Chinese brain-computer interface companies

The US Treasury proposed rules on 22 October 2026 that would prohibit US persons from most new non-public investments in companies that develop or produce brain-computer interfaces and are based in, or owned or controlled from, China, Hong Kong or Macau. The definition covers invasive and non-invasive systems and their software. Brain-computer interfaces sit in the rule's prohibited tier, with no notify-only option, no technical threshold and no small-deal exemption for direct investments. Comments are due by 7 December 2026.

Oct 24, 2026 · 10 min read

Policy & Regulation

A Chinese expert led the new international blueprint for brain-computer interfaces

ISO and IEC published ISO/IEC 27572:2026, a voluntary international reference architecture for brain-computer interfaces, on 3 September 2026. China's market regulator said in mid-October that a Chinese expert led the project, with experts from countries including Italy, South Korea, the UK, India, the US, Japan, Sweden, Finland, Australia and Germany. The subcommittee behind it, ISO/IEC JTC 1/SC 43, has China's national standards body as its secretariat and a Chinese chair, and its scope is under review.

Oct 23 · 6 min read

Industry News

Emotiv puts brain-computer interface apps in the browser

Emotiv's new site emotiv.dev offers seven browser-based brain-computer interface apps for its EEG headsets and keeps their brain data on the user's computer. Using the apps with a real headset requires consent to EmotivIQ, Emotiv's cloud AI service. Under terms updated in August and September, that consent lets Emotiv train its Large Brain Model on pseudonymised brain data from its own apps and cloud, and license the trained model to partners.

Oct 23 · 5 min read

Market Moves

Founders Fund and the OpenAI Startup Fund co-lead Coherence Neuro's US$45 million round

Coherence Neuro, which is developing a brain implant to monitor and treat brain tumours, announced a US$45 million round, which it calls its Series A, on 21 October 2026, co-led by Founders Fund and the OpenAI Startup Fund. The money is for its first long-term human trial in glioblastoma, an application for FDA Breakthrough Device designation and preclinical work in pancreatic cancer. Chief executive Ben Woodington says OpenAI will not have access to any brain or health data the company generates.

Oct 22 · 5 min read

Industry News

Phantom Neuro implants its prosthetic hand sensor in its first patients

Phantom Neuro announced on 20 October 2026 that the first participants in its CYBORG study in Melbourne have received Phantom X, a sensor placed under the skin of the forearm that reads muscle signals and relays them wirelessly to control a prosthetic hand. Two people have been implanted so far, at Cabrini Health, in procedures of about an hour without general anaesthetic. The study can enrol up to 10 people, and Phantom Neuro plans to use the results to support a US FDA application.

Oct 21 · 4 min read

Market Moves

Paradromics teams up with Siemens Healthineers on brain scans for implant surgery

Paradromics, the Austin company testing its Connexus brain implant in the Connect-One study, announced a collaboration with Siemens Healthineers on 19 October 2026. The two plan to build one imaging workflow for brain-computer interface patients, from choosing candidates and planning surgery to confirming where the implant sits, combining scans including structural and functional MRI, blood-vessel imaging and CT. It starts with speech and is ultimately meant for medical centres that use Siemens Healthineers scanners. Financial terms were not disclosed.

Oct 20 · 4 min read

Market Moves

Precision Neuroscience hires two Nevro veterans for its commercial push

Precision Neuroscience has named Nevro founder Konstantinos Alataris as president and Katherine Neuenfeldt, who led the US launch of Nevro's spinal cord stimulator and its insurance coverage work, as senior vice president of commercial strategies. The appointments, announced on 15 October 2026, follow a $250 million Series D. Neuenfeldt is the third executive hired to lead commercial work at Precision since 2024, after Jayme Strauss and John Woock.

Oct 18 · 3 min read

Research

Penn's AI app lets epilepsy patients chat with their brain monitors

A University of Pennsylvania app let 13 epilepsy patients in hospital text questions to the system reading their brain activity and mark its seizure alarms as right or wrong, in a study published in Nature Medicine on 13 October 2026. In a simulation run afterwards, retraining on those answers cut false alarms by 80 per cent. Penn holds a provisional patent, has named no commercial partner, and is preparing a Parkinson's study.

Oct 16 · 4 min read

Industry News

Science Corp reports first sign PRIMA works in an inherited eye disease

Science Corporation said on 13 October 2026 that the first patient with Stargardt disease, a rare inherited cause of central vision loss, to receive its PRIMA retinal implant saw a letter in his first rehabilitation session and read a word in his second. It is the first clinical result Science has reported from PRIMA outside geographic atrophy, the form of age-related macular degeneration the implant is sold for in Europe and the UK. The claim rests on one patient and a company video, with no acuity data or publication.

Oct 15 · 4 min read